

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

Welcome to MESSENGER at USPTO

The USPTO production files are current through:

18 JAN 1994 for U.S. Patent Text Data.

18 JAN 1994 for U.S. Current Classification data.

18 JAN 1994 for U.S. Patent Image Data.

* PLEASE USE 305-9000 FOR NEW TELEPHONE NUMBER *

DISCLAIMER:

Neither the United States Government, nor any agency thereof, nor any of their contractors, subcontractors or employees make any warranty, expressed or implied, including any warranty of marketability of fitness for a particular purpose; nor assumes any legal liability or responsibility for any party's use, or the results of such, of the data.

There is a new number to call for APS help: 305-9000.

The Help Desk staff at this number will handle all APS related questions. Current hours are 6:30 am to 9:00 pm Monday through Friday and 7:30 am to 5:00 pm Saturday.

HOURS TO ACCESS MESSENGER ARE 6:30 AM to 9:00 PM

MONDAY THRU FRIDAY AND 7:30 AM to 5:00 PM SATURDAY.

FILE 'USPAT' ENTERED AT 14:32:53 ON 21 JAN 94

W E L C O M E T O T H E

U . S . P A T E N T T E X T F I L E

=> s (antivenin or venom?) and (fab or ((f)(W)(ab))

UNMATCHED LEFT PARENTHESIS 'AND (FAB'

=> s (antivenin or venom?) and (fab or ((f)(W)(ab)))

4 ANTIVENIN

890 VENOM?

3238 FAB

524985 F

18918 AB

1075 (F)(W)(AB)

L1 80 (ANTIVENIN OR VENOM?) AND (FAB OR ((F)(W)(AB)))

=> t 11 cit 1-80

1. 5,279,956, Jan. 18, 1994, Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C; John H. Griffin, et al., 435/183; 424/85.8; 435/69.2, 70.21, 240.27; 436/536; 514/12; 530/300, 324, 326, 328, 381, 382, 383, 384, 388.25, 388.26, 389.3, 412 [IMAGE AVAILABLE]

2. 5,279,937, Jan. 18, 1994, Use of macroglobulins to improve the signal-to-background ratio in affinity binding assays; Gerald E. Rowe, 435/6, 7.92, 7.93, 23, 971; 436/538 [IMAGE AVAILABLE]

3. 5,278,144, Jan. 11, 1994, Antithrombosis agents; David Wolf, 514/12; 424/94.64; 435/69.1, 69.2, 69.6; 514/2, 8; 530/384, 395 [IMAGE AVAILABLE]
4. 5,278,064, Jan. 11, 1994, Amycolatopsis mediterranei strains useful to prepare A87689 compounds; Dennis R. Berry, et al., 435/252.1; 424/122; 435/195, 253.2, 253.5 [IMAGE AVAILABLE]
5. 5,273,885, Dec. 28, 1993, Conjugates of monophenyl thyroid analogs useful in assays; Jill M. Visor, et al., 435/7.93, 7.9, 975 [IMAGE AVAILABLE]
6. 5,270,170, Dec. 14, 1993, Peptide library and screening method; Peter J. Schatz, et al., 435/7.37, 252.33, 320.1; 935/11 [IMAGE AVAILABLE]
7. 5,260,427, Nov. 9, 1993, Nucleosidylphosphite-borane compounds and method of making the same; Bernard F. Spielvogel, et al., 536/17.1; 435/91.5; 558/72; 562/11 [IMAGE AVAILABLE]
8. 5,256,642, Oct. 26, 1993, Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof; Douglas T. Fearon, et al., 514/8; 424/94.63, 94.64; 435/215, 216; 514/2; 530/350 [IMAGE AVAILABLE]
9. 5,252,712, Oct. 12, 1993, Purified antibodies which specifically bind human abnormal prothrombin; Bruce E. Furie, et al., 530/389.3; 435/240.27; 530/388.25 [IMAGE AVAILABLE]
10. 5,246,968, Sep. 21, 1993, Glutamate receptor inhibitor; Terumi Nakajima, et al., 514/616; 564/153 [IMAGE AVAILABLE]
11. 5,242,945, Sep. 7, 1993, Tetronic and thiotetronic acid derivatives as phospholipase A.sub.2 inhibitors; Craig E. Caufield, et al., 514/473, 445, 826; 549/64, 65, 313, 314, 316, 317 [IMAGE AVAILABLE]
12. 5,242,810, Sep. 7, 1993, Bifunctional inhibitors of thrombin and platelet activation; John M. Maraganore, et al., 435/69.2, 69.6, 69.7, 172.3, 214, 252.3, 252.33, 320.1; 530/324, 856; 536/23.1, 23.4, 23.5; 930/250 [IMAGE AVAILABLE]
13. 5,229,516, Jul. 20, 1993, Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase; John H. Musser, et al., 546/172, 152, 174, 175, 176, 180 [IMAGE AVAILABLE]
14. 5,229,500, Jul. 20, 1993, Brain derived neurotrophic factor; Yves-Alain Barde, et al., 530/399; 424/88; 435/69.1; 530/350, 387.9, 389.2, 412, 413 [IMAGE AVAILABLE]
15. 5,227,469, Jul. 13, 1993, Platelet aggregation inhibitors from the leech; Robert A. Lazarus, et al., 530/324, 326 [IMAGE AVAILABLE]
16. 5,227,397, Jul. 13, 1993, Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels; Nicholas A. Saccomano, et al., 514/419, 12; 548/495 [IMAGE AVAILABLE]
17. 5,225,571, Jul. 6, 1993, Substituted dihydroxy-bis-[5-hydroxy-2(5H)-furanone-4-yl]-alkanes as anti-inflammatory agents; Gary C. M. Lee, 549/222, 313 [IMAGE AVAILABLE]

[illegible]

1. The first part of the document is a header section containing the following information:

- Page: 1
- Date: 10/10/2010
- Time: 10:10
- Author: [Name]
- Subject: [Subject]

2. The second part of the document is a table with the following structure:

Item	Description	Value
1	[Description]	[Value]
2	[Description]	[Value]
3	[Description]	[Value]
4	[Description]	[Value]
5	[Description]	[Value]
6	[Description]	[Value]
7	[Description]	[Value]
8	[Description]	[Value]
9	[Description]	[Value]
10	[Description]	[Value]
11	[Description]	[Value]
12	[Description]	[Value]
13	[Description]	[Value]
14	[Description]	[Value]
15	[Description]	[Value]
16	[Description]	[Value]
17	[Description]	[Value]
18	[Description]	[Value]
19	[Description]	[Value]
20	[Description]	[Value]
21	[Description]	[Value]
22	[Description]	[Value]
23	[Description]	[Value]
24	[Description]	[Value]
25	[Description]	[Value]
26	[Description]	[Value]
27	[Description]	[Value]
28	[Description]	[Value]
29	[Description]	[Value]
30	[Description]	[Value]
31	[Description]	[Value]
32	[Description]	[Value]
33	[Description]	[Value]
34	[Description]	[Value]
35	[Description]	[Value]
36	[Description]	[Value]
37	[Description]	[Value]
38	[Description]	[Value]
39	[Description]	[Value]
40	[Description]	[Value]
41	[Description]	[Value]
42	[Description]	[Value]
43	[Description]	[Value]
44	[Description]	[Value]
45	[Description]	[Value]
46	[Description]	[Value]
47	[Description]	[Value]
48	[Description]	[Value]
49	[Description]	[Value]
50	[Description]	[Value]
51	[Description]	[Value]
52	[Description]	[Value]
53	[Description]	[Value]
54	[Description]	[Value]
55	[Description]	[Value]
56	[Description]	[Value]
57	[Description]	[Value]
58	[Description]	[Value]
59	[Description]	[Value]
60	[Description]	[Value]
61	[Description]	[Value]
62	[Description]	[Value]
63	[Description]	[Value]
64	[Description]	[Value]
65	[Description]	[Value]
66	[Description]	[Value]
67	[Description]	[Value]
68	[Description]	[Value]
69	[Description]	[Value]
70	[Description]	[Value]
71	[Description]	[Value]
72	[Description]	[Value]
73	[Description]	[Value]
74	[Description]	[Value]
75	[Description]	[Value]
76	[Description]	[Value]
77	[Description]	[Value]
78	[Description]	[Value]
79	[Description]	[Value]
80	[Description]	[Value]
81	[Description]	[Value]
82	[Description]	[Value]
83	[Description]	[Value]
84	[Description]	[Value]
85	[Description]	[Value]
86	[Description]	[Value]
87	[Description]	[Value]
88	[Description]	[Value]
89	[Description]	[Value]
90	[Description]	[Value]
91	[Description]	[Value]
92	[Description]	[Value]
93	[Description]	[Value]
94	[Description]	[Value]
95	[Description]	[Value]
96	[Description]	[Value]
97	[Description]	[Value]
98	[Description]	[Value]
99	[Description]	[Value]
100	[Description]	[Value]

3. The third part of the document is a footer section containing the following information:

- Page: 1
- Date: 10/10/2010
- Time: 10:10
- Author: [Name]
- Subject: [Subject]

(The following information was obtained from the records maintained by the Bureau of Census, U.S. Department of Commerce.)

1. The first part of the document is a header section containing the following information:

- 1.1. The name of the company: "The First National Bank of the United States"
- 1.2. The address of the company: "1000 Main Street, New York, New York 10001"
- 1.3. The date of the document: "January 1, 1980"

2. The second part of the document is a body section containing the following information:

- 2.1. The name of the person: "John Doe"
- 2.2. The address of the person: "1234 Main Street, New York, New York 10001"
- 2.3. The date of the document: "January 1, 1980"

3. The third part of the document is a footer section containing the following information:

- 3.1. The name of the company: "The First National Bank of the United States"
- 3.2. The address of the company: "1000 Main Street, New York, New York 10001"
- 3.3. The date of the document: "January 1, 1980"

1. The first part of the document is a header section containing the following information:

- Page number: 1
- Date: 10/10/2019
- Time: 10:10
- Location: 10/10/2019
- Page number: 1

2. The second part of the document is a table with the following columns:

Item	Quantity	Unit	Price	Total
1.000	1.000	kg	1.000	1.000
2.000	2.000	kg	2.000	2.000
3.000	3.000	kg	3.000	3.000
4.000	4.000	kg	4.000	4.000
5.000	5.000	kg	5.000	5.000
6.000	6.000	kg	6.000	6.000
7.000	7.000	kg	7.000	7.000
8.000	8.000	kg	8.000	8.000
9.000	9.000	kg	9.000	9.000
10.000	10.000	kg	10.000	10.000
11.000	11.000	kg	11.000	11.000
12.000	12.000	kg	12.000	12.000
13.000	13.000	kg	13.000	13.000
14.000	14.000	kg	14.000	14.000
15.000	15.000	kg	15.000	15.000
16.000	16.000	kg	16.000	16.000
17.000	17.000	kg	17.000	17.000
18.000	18.000	kg	18.000	18.000
19.000	19.000	kg	19.000	19.000
20.000	20.000	kg	20.000	20.000
21.000	21.000	kg	21.000	21.000
22.000	22.000	kg	22.000	22.000
23.000	23.000	kg	23.000	23.000
24.000	24.000	kg	24.000	24.000
25.000	25.000	kg	25.000	25.000
26.000	26.000	kg	26.000	26.000
27.000	27.000	kg	27.000	27.000
28.000	28.000	kg	28.000	28.000
29.000	29.000	kg	29.000	29.000
30.000	30.000	kg	30.000	30.000
31.000	31.000	kg	31.000	31.000
32.000	32.000	kg	32.000	32.000
33.000	33.000	kg	33.000	33.000
34.000	34.000	kg	34.000	34.000
35.000	35.000	kg	35.000	35.000
36.000	36.000	kg	36.000	36.000
37.000	37.000	kg	37.000	37.000
38.000	38.000	kg	38.000	38.000
39.000	39.000	kg	39.000	39.000
40.000	40.000	kg	40.000	40.000
41.000	41.000	kg	41.000	41.000
42.000	42.000	kg	42.000	42.000
43.000	43.000	kg	43.000	43.000
44.000	44.000	kg	44.000	44.000
45.000	45.000	kg	45.000	45.000
46.000	46.000	kg	46.000	46.000
47.000	47.000	kg	47.000	47.000
48.000	48.000	kg	48.000	48.000
49.000	49.000	kg	49.000	49.000
50.000	50.000	kg	50.000	50.000
51.000	51.000	kg	51.000	51.000
52.000	52.000	kg	52.000	52.000
53.000	53.000	kg	53.000	53.000
54.000	54.000	kg	54.000	54.000
55.000	55.000	kg	55.000	55.000
56.000	56.000	kg	56.000	56.000
57.000	57.000	kg	57.000	57.000
58.000	58.000	kg	58.000	58.000
59.000	59.000	kg	59.000	59.000
60.000	60.000	kg	60.000	60.000
61.000	61.000	kg	61.000	61.000
62.000	62.000	kg	62.000	62.000
63.000	63.000	kg	63.000	63.000
64.000	64.000	kg		

(continued)

1. The first step is to identify the problem or question that needs to be answered. This involves understanding the context and the specific requirements of the task.

[illegible]

ВН. 01.112.719, май 12, 1992, копию предоставил Владимир Бурцев; Игорь А. Мещеряков, ат. 01., август 18, с. 10, 19, 21, 26, 1993 в архиве [ИМЯ] AVAILABLE

[illegible]

B-1, 7, 8001, 201, 1200, 12, 1942; B-1 (SUBSTITUTED & N-SUBSTITUTED ANTIPODAMIDES);
STABOL: 1, SUBSTITUTED 2(10); TITANOLONE AND B-1 (N-SUBSTITUTED ANTIPODAMIDES);
STABOL: 1, SUBSTITUTED 2(10); TITANOLONE AD AND STABOL TETRAHYDROXY DERIVATES; CARY M. S.
196, 544/222, 544/224, 111, 114, 101; 544/212, 111, 114 [IMAGE AVAILABLE]

44. 5/07/1832, Dec. 10, 1991, KINONUCLEOTIDE REDUCTASE INHIBITORS; Yvan Guindon, et al.; 514/13, 12, 17, 18, 19; 530/325, 327, 328, 329 [IMAGE AVAILABLE]

42. 0,066,789, NOV. 14, 1991, "TARGETING SUBSTANCE-DIAGNOSTIC/THERAPEUTIC AGENT CONJUGATES HAVING SCOTT BASE LINKAGES; APANTHAGARI SRINIVASAN, ET AL., 030/191-2, 363, 191-4 IMAGE AVAILABLE!

46. J. HEBB, b. 71, NOV. 19, 1941, KILGID ACID DERIVATIVES AS PROSPEROIDASE
A-SUB-2 INHIBITORS; UTAID K. CAUTION, 214/423 (IMAGE AVAILABLE)

47. 5,1166,543. NOV. 19, 1991. SYNTHETIC PEPTIDE-BASED ANTI-RANTES

52. 5,031,578, Jun. 4, 1991, 2-Amino phenylacetic acid derivatives; Amador A. Falla, et al., 546/174, 175 [IMAGE AVAILABLE]

53. 5,013,330, May 7, 1991, Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers; Eiko Ohtsuka, et al., 536/25.1, 25.1, 25.3, 25.34, 26.7, 26.72, 26.9, 27.63, 27.31, 28.5, 28.53 [IMAGE AVAILABLE]

54. 5,001,656, Mar. 19, 1991, Preparation of monoclonal antibodies; Solomon H. Snyder, et al., 435/70.21, 172.2, 173.6, 240.27; 935/93 [IMAGE AVAILABLE]

55. 4,960,712, Oct. 2, 1990, System and method for complement pathway analysis; Argyrios N. Theofilopoulos, et al., 436/501; 436/965, 973; 436/507, 512, 536, 539, 543, 594, 621 [IMAGE AVAILABLE]

56. 4,946,733, Aug. 7, 1990, Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications; Guy Delespessis, 530/333.23; 424/85.6; 435/7.5, 70.21, 172.2, 183, 240.27, 243, 264; 530/333.73, 391.3, 362, 366, 368; 935/95, 100, 102, 103, 104, 106, 107, 109, 110 [IMAGE AVAILABLE]

57. 4,939,240, Jul. 3, 1990, Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy; Tsann M. Chu, et al., 530/333.35; 424/1.1, 35.3, 35.31; 435/70.21, 183, 240.27; 530/391.3, 391.7, 393, 399; 935/104, 107 [IMAGE AVAILABLE]

58. 4,930,817, Nov. 14, 1989, O-functionalized derivatives of substituted isoquinolin-3-ols having cardiotonic and/or phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties; Ramesh M. Kanojia, et al., 514/309, 210, 235.2, 253; 544/123, 363; 546/141 [IMAGE AVAILABLE]

59. 4,876,190, Oct. 24, 1989, Peridinin-chlorophyll complex as fluorescent label; Diether J. Recktenwald, 435/7.2, 7.21, 7.23, 7.24, 963; 436/513, 537, 546, 600; 530/302 [IMAGE AVAILABLE]

60. 4,867,973, Sep. 19, 1989, Antibody-therapeutic agent conjugates; John W. F. Coors, et al., 424/85.91, 85.3, 86, 87; 514/2, 6, 8; 530/333.7, 333.9, 391.9, 323, 364, 366; 930/10, 22 [IMAGE AVAILABLE]

61. 4,645,355, Jul. 15, 1987, Immunoregulation of lymph. induction, lymph. response and auto induction: Peter C. Hooper, 435/7.4, 4, 7.6, 12, 13, 104, 311, 435/300 [IMAGE AVAILABLE]

62. 4,645,351, Jul. 15, 1987, Initiating proliferation particles: John D. Sullivan, et al., 435/35.1, 100, 435/311 [IMAGE AVAILABLE]

63. 4,655,340, Jul. 11, 1987, Method for detection of antigen expression: Immunoregulation: John Hooper, et al., 435/35.6, 311, 435/35.1, 330/300.1, 330.1, 414, 410, 300 [IMAGE AVAILABLE]

64. 4,774,340, Sep. 17, 1988, Small molecule growth activating particles: John Hooper, et al., 330/314, 317, 310, 330, 330/10, 100, 310.011 [IMAGE AVAILABLE]

65. 4,785,310, Sep. 9, 1988, Immunoregulatory agents and methods useful in human tumor perturbation and human chorionic perturbation determinations: Peter C. Hooper, et al., 435/7.31, 7.13, 7.4, 12, 310, 435/35, 330, 340, 330, 311, 310, 310, 330/301, 304, 300.10, 300 [IMAGE AVAILABLE]

66. 4,784,433, Mar. 17, 1988, Small molecule growth activating particles: John Hooper, et al., 330/314, 435/35.31, 317/1, 11, 11, 330/330, 400, 400, 330, 330/10, 10, 100, 310.011 [IMAGE AVAILABLE]

67. 4,714,705, Jul. 11, 1987, 4 nitrogen substituted benzimidazole compounds having antitumor, photophosphorescent function and initiating properties and/or tumor regenerating properties: Thomas H. Hooper, et al., 314/300, 340/141 [IMAGE AVAILABLE]

68. 4,787,350, Nov. 17, 1987, Synthetic peptide based anti rabies compositions and methods: James W. Patrick, et al., 424/300, 330/10, 220 [IMAGE AVAILABLE]

69. 4,675,207, Jun. 13, 1987, Monoclonal antibody directed to human ganglioside GD.sub.2: Ralph A. Reisfeld, et al., 435/7.13, 424/35.6, 35.31, 435/7.31, 70.11, 171.2, 240.17, 340, 375, 435/510, 510, 540, 313, 530/307.3, 300.1, 300.35, 301.3, 300, 300, 300, 305/30, 35, 100, 107 [IMAGE AVAILABLE]

70. 4,671,044, Jun. 9, 1987, Murine monoclonal antibody combining site to human G3b receptor (CR1): Robert D. Schreiber, 435/301, 435/4, 7.21, 7.24, 7.25, 70.11, 171.2, 240.17, 310, 300, 375, 435/504, 500, 507, 512, 510, 530, 540, 540, 313, 321, 335/104, 110 [IMAGE AVAILABLE]

71. 4,671,950, Jun. 9, 1987, Antibody conjugates for the delivery of compounds to target sites: John D. Redwell, et al., 424/35.01, 1.1, 35.3, 36, 37, 514/1, 6, 9, 530/300.6, 301.5, 301.9, 320, 304, 306 [IMAGE AVAILABLE]

72. 4,661,347, Apr. 29, 1987, Cytotoxic compositions: Hans J. Muller-Eberhard, et al., 424/35.01, 435/189, 530/300.35, 301.7, 301.9, 305, 402, 403, 404, 409 [IMAGE AVAILABLE]

73. 4,652,629, Mar. 24, 1987, Synthetic peptide-based anti-rabies compositions and methods: James W. Patrick, et al., 530/326, 327, 328, 329, 330, 403, 930/10, 220 [IMAGE AVAILABLE]

74. 4,642,284, Feb. 10, 1987, Method and system for detection of complement pathway activation: Neil Cooper, et al., 435/7.94, 4, 7.4, 28,

(Item 1 from file: 155)

04954594 83187594

Simplified preparation of rabbit Fab fragments.

Coulter A; Harris R

J Immunol Methods Apr 29 1983, 59 (2) p199-203, ISSN 0022-1759

Journal Code: IFE

Languages: ENGLISH

Document type: JOURNAL ARTICLE

JOURNAL ANNOUNCEMENT: 8308

Subfile: INDEX MEDICUS

Papain attached to solid-phase CH-Sepharose 4B was used to digest rabbit IgG. Protein A-Sepharose CL-4B was used to remove undigested IgG and Fc fragments. Pure Fab fragments free of IgG, Fc fragments and papain were readily obtained by this procedure with a yield of about 75%. Polyacrylamide gel electrophoresis of the Fab in the presence of sodium dodecyl sulphate gave a single band under both reducing and non-reducing conditions. The molecular weight of the Fab determined by sedimentation equilibrium was 49,200. Unlike the IgG, the Fab obtained did not form precipitin lines when used in immunoelectrophoresis.

Tags: Animal

Descriptors: *Immunoglobulins, Fab--Isolation and Purification--IP; Chromatography, Ion Exchange; Electrophoresis, Polyacrylamide Gel; IgG --Analysis--AN; Immunoenzyme Techniques; Immunoglobulins, Fab--Analysis--AN ; Mice; Molecular Weight; Neurotoxins--Immunology--IM; Rabbits; Snake Venoms--Immunology--IM

CAS Registry No.: 0 (Immunoglobulins, Fab); 0 (Neurotoxins); 0 (Snake Venoms)

6